The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeu...( McElvaney's research will examine how...)

McElvaney's research will examine how infusions of AAT reduce the levels of destructive molecules known as reactive oxygen species (ROS). ROS are produced by neutrophils circulating in the lungs. AAT inhibits the activity of neutrophils and thus the production of ROS. When AAT is deficient, ROS levels rise dangerously and inflict damage to lung tissue. McElvaney's team will study how infusions of AAT bind to neutrophils.

Gelling's research will investigate which variants of the alpha-1 antitrypsin gene predispose individuals with AAT deficiency to liver damage and which gene variants are protective. Researchers have previously shown that individuals with the "Z" mutation of AAT gene are at increased risk for producing sticky AAT proteins that clump in the liver and form plaques. Yet scientists have no way of predicting which individuals will be affected. Gelling's team will use genetically engineered baker's yeast to produce the sticky proteins and then analyze precisely how the proteins malfunction.

About the Alpha-1 Foundation:

The mission of the Alpha-1 Foundation is to provide the leadership and resources that will result in increased research, improved health, worldwide detection, and a cure for Alpha-1 Antitrypsin Deficiency. For more information, please visit: www.alphaone.org.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis.

http://www.talecris.com '/>"/>